
    
      A US based nonrandomized, sequential cohort, crossover trial to assess pharmacokinetics,
      safety and tolerability of brexpiprazole in children ages 6 to <13 years with CNS disorders
      who are receiving antipsychotic treatment for their medical condition.
    
  